Previous 10 | Next 10 |
- Expedited Access to OXLUMO Aims to Support Children and Adults Living with PH1 who Face Inevitable Disease Progression and Irreversible Kidney Damage in the Absence of New Treatment Options - - New Value-Based Agreement Framework Includes an Innovative Patient Need Adjustmen...
– First RNAi Therapeutic Approved in U.S. for Use in Both Children and Adults, and Third RNAi Medicine to Receive FDA Approval in Less than Three Years – – Approval Based on Results from Both ILLUMINATE-A and ILLUMINATE-B Phase 3 Studies, Demonstrating Cli...
The FDA has approved Alnylam Pharmaceuticals' (ALNY) Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. Patients with PH1 produce far too much oxalate, which can combine with calcium to cause kidney stones and deposi...
A head and shoulders pattern has formed in the chart of Alnylam Pharmaceuticals Inc. (ALNY). A breakdown could soon follow. Learn how to profit from this trade. A head and shoulders pattern has developed in the chart of Alnylam Pharmaceuticals Inc. ( ALNY ) and a breakdown is expected soo...
The European Commission has granted marketing authorization to Alnylam Pharmaceuticals' (ALNY) Oxlumo (lumasiran), an RNAi therapeutic, for the treatment of primary hyperoxaluria type 1 ((PH1)) in all age groups, a rare disorder that mainly affects the kidneys and results ...
– OXLUMO is the First Therapeutic Approved for the Treatment of PH1, and the Only Therapy Proven to Lower Harmful Oxalate Levels that Drive the Progression of PH1 Disease – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, tod...
Alnylam exceeded third-quarter sales expectations, with a stronger-than-expected recovery in Onpattro and healthy Givlaari sales. Another look at the Phase I ALN-AGT study showed double-digit blood pressure reductions with a clean safety profile and convenient dosing. An upcoming ...
Alnylam Pharmaceuticals ([[ALNY]] +2.6%) has announced interim data from ongoing Phase 1 study of ALN-AGT RNAi therapeutic targeting liver-expressed angiotensinogen ((AGT)), a hormone system that regulates blood pressure and fluid balance, for the treatment of hypertension. Results were prese...
Image source: The Motley Fool. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Q3 2020 Earnings Call Nov 5, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Alnylam Pharmaceuticals Inc (ALNY) Q3 2020 Earnings Call Transcr...
Alnylam Pharmaceuticals, Inc (ALNY) Q3 2020 Earnings Conference Call November 05, 2020 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Andy Orth - Senior Vice President...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...